Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Vor Biopharma Inc VOR

Healthcare Biotechnology
Vor Biopharma Inc. is a clinical-stage cell and genome engineering therapy company. The Company is engaged in combining a novel patient engineering approach with targeted therapies to provide solutions for patients suffering from hematological malignancies. Its proprietary platform leverages expertise in hematopoietic stem cell (HSC) biology, genome engineering and targeted therapy development... see more

Recent & Breaking News (NDAQ:VOR)

Vor Bio Provides Clinical Update Further Validating Approach of Using Shielded Transplants to Deliver Targeted Therapies; Receives Supportive Feedback from FDA Regarding Registrational Trial Design

GlobeNewswire December 9, 2024

Vor Bio to Participate in the Stifel 2024 Healthcare Conference

GlobeNewswire November 12, 2024

Vor Bio Reports Third Quarter 2024 Financial Results and Provides Company Update

GlobeNewswire November 7, 2024

Vor Bio Appoints Seasoned Healthcare Institutional Investor, Han Choi, M.D., LL.M., as Chief Financial Officer

GlobeNewswire September 30, 2024

New Clinical Data Validates Vor Bio's Approach of Using Shielded Transplants to Deliver Targeted Therapies

GlobeNewswire September 5, 2024

Vor Bio to Participate in Upcoming Investor Conferences

GlobeNewswire August 28, 2024

Vor Bio Reports Second Quarter 2024 Financial Results and Provides Company Update

GlobeNewswire August 8, 2024

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire August 2, 2024

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire July 9, 2024

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire June 4, 2024

Vor Bio Reports First Quarter 2024 Financial Results and Provides Company Update

GlobeNewswire May 9, 2024

Vor Bio to Participate in Upcoming Investor Conferences

GlobeNewswire May 6, 2024

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire May 3, 2024

Vor Bio Appoints Accomplished Oncology and Cancer Immunotherapy R&D Executive, Fouad Namouni, M.D., to its Board of Directors

GlobeNewswire May 2, 2024

Vor Bio to Participate in Upcoming Investor Conferences

GlobeNewswire April 1, 2024

Vor Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update

GlobeNewswire March 20, 2024

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire March 5, 2024

Vor Bio to Participate in Upcoming Investor Conferences

GlobeNewswire March 4, 2024

Vor Bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

GlobeNewswire February 7, 2024

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire February 2, 2024